R. Wise, G. Criner, M. Dransfield, M. Han, C. E. Jones, S. Lettis, F. Martinez, S. Pascoe, H. Quasny, David A. Lipson
{"title":"告知慢性阻塞性肺病治疗途径(IMPACT研究)-单吸入器三联治疗(糠酸氟替卡松/乌莫列地铵/维兰特罗)与糠酸氟替卡松/维兰特罗和乌莫列地铵/维兰特罗治疗慢性阻塞性肺病患者:基于北美地区分析的结果","authors":"R. Wise, G. Criner, M. Dransfield, M. Han, C. E. Jones, S. Lettis, F. Martinez, S. Pascoe, H. Quasny, David A. Lipson","doi":"10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a3309","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":311626,"journal":{"name":"B45. COPD: TREATMENT","volume":"67 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2019-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"InforMing the PAthway of COPD Treatment (IMPACT Study)-Single Inhaler Triple Therapy (Fluticasone Furoate/Umeclidinium/Vilanterol) Versus Fluticasone Furoate/Vilanterol and Umeclidinium/Vilanterol in Patients with COPD: Results Based on an Analysis of the North American Region\",\"authors\":\"R. Wise, G. Criner, M. Dransfield, M. Han, C. E. Jones, S. Lettis, F. Martinez, S. Pascoe, H. Quasny, David A. Lipson\",\"doi\":\"10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a3309\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":311626,\"journal\":{\"name\":\"B45. COPD: TREATMENT\",\"volume\":\"67 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"B45. COPD: TREATMENT\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a3309\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"B45. COPD: TREATMENT","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a3309","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
InforMing the PAthway of COPD Treatment (IMPACT Study)-Single Inhaler Triple Therapy (Fluticasone Furoate/Umeclidinium/Vilanterol) Versus Fluticasone Furoate/Vilanterol and Umeclidinium/Vilanterol in Patients with COPD: Results Based on an Analysis of the North American Region